7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/23/2013

Company Name Symbol %Change
WESTELL TECH WSTL
6.67%
STEIN MART I SMRT
5.38%
ALLIANCE FIB AFOP
5.21%
DAWSON GEOPH DWSN
4.33%
MARRIOTT VAC VAC
3.27%

W.R. Berkley Corp. (WRB)

by Zacks Equity Research

October 11, 2011 | Comments : 0 Recommended this article: (0)
WRB

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We have downgraded our recommendation on W.R. Berkley Corp. (WRB) to Underperform from Neutral, reflecting slightly lower investment yield assumptions and modestly higher loss ratio forecasts which would eat into underwriting margins.

Berkley has been hurt by soft pricing conditions and increasing competition. The trend of loss claims shows a divergence from declining losses over the past several years. An increase in claim costs will offset the premium rate improvement seen lately, thus pressurizing underwriting margins.

Our six-month target price of $27.00 per share equates to about 10.6x our earnings estimate for 2011. Combined with the $0.32 per share annual dividend, this target price implies an expected negative return of 8.2% over that period.

Read the full reports :

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.